Biogen (BIIB) PT Lowered to $343 at Wells Fargo
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $219.05 +1.41%
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 3 | Down: 10 | New: 43
Rating Summary:
28 Buy, 15 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 3 | Down: 10 | New: 43
Join SI Premium – FREE
Wells Fargo analyst Mohit Bansal lowered the price target on Biogen (NASDAQ: BIIB) to $343.00 (from $350.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Biogen's Empaveli cuts proteinuria 75% in teens with rare kidney disease
- Stryker (SYK) PT Lowered to $385 at Canaccord
- Fluence Energy Inc. (FLNC) PT Lowered to $5 at BNP Paribas Exane
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
